TOMBOLA randomised controlled trial
Immediate colposcopy referral in women with low-grade abnormal results on cervical cytology detects more CIN2 or worse lesions than cytological surveillance in primary care, but might lead to overtreatment Most women with a Pap smear showing minor abnormalities, detected in the framework of cervical cancer screening, do not have or will not develop clinically signifi cant disease. Minor cytological abnormalities are classifi ed by UK cytological criteria as borderline or mild dyskaryosis, which can be translated into international terminology as ASCUS (atypical squamous cells of undetermined signifi cance) or LSIL (low-grade squamous intraepithelial lesions), respectively.
According to a recent meta-analysis, the absolute risk of underlying high-grade cervical intraepithelial neoplasia (grade II or III or worse (CIN2/3+)) among women with ASCUS is on average 9-10% for CIN2+ and 4-5% for CIN3+. For women with LSIL, these risks are about 1.5 to 2 times as high. 1 These risks are 10 to 30 times higher than for women with normal cytology. The probability that high-grade CIN will progress to invasive cancer is not well known, as these lesions are usually treated. However, from historical data, it was estimated that CIN3 incurs a probability of progressing to invasive cancer of 12-30%, depending on lesion size and follow-up time, 2 3 whereas for CIN2 this probability is substantially less. Moreover, treatment of CIN by excision is associated with obstetrical morbidity. 4 5 Therefore, women with minor cytological lesions require careful management that balances future cancer risk, adverse effects and costs.
The TOMBOLA trial enrolled more than 4000 women aged 25-59 years with borderline or mild dyskaryosis to evaluate two management options-repetition of Pap smears or immediate referral to colposcopy-to assess the detection of CIN2+ and CIN3+ over a period of 3 years, as well as gynaecological and psychological side effects. At randomisation, a sample was taken for highrisk human papillomavirus (hrHPV) DNA testing, but the results did not interfere with management. Moreover, within the immediate-colposcopy arm, two algorithms were compared: immediate treatment of colposcopically visible lesions or treatment based on the histological examination of colposcopy-targeted biopsies. The trial included fi nal colposcopy assessment for all participants.
Repeat cytology identifi ed 269 of the 350 cumulative diagnoses of CIN2+ (longitudinal sensitivity of 76.9%) and 168/193 CIN3+ (87.0%). The sensitivity of immediate colposcopy and subsequent follow-up was 435/468 (92.3%) for CIN2+ and 231/238 for CIN3+ (97.1%).
Immediate colposcopy was signifi cantly more sensitive than cytology-based follow-up (ratio 1.21, 95% CI 1.14 to 1.29, for CIN2+; 1.12, 95% CI 1.05 to 1.18 for CIN3+) but was associated with more side effects (pain, haemorrhage, discharge, p < 0.001). The authors interpret the lower detection rate ratio for CIN3+ compared with CIN2+, in particular among younger women and women with mild dyskaryosis, as an indication of overdiagnosis in the immediate-colposcopy arm. Cost-effectiveness analyses did not indicate superiority of any management option.
The TOMBOLA trial was adequately randomised, but concealment of randomisation was unclear. Blinding of allocation for participants and assessors was not possible but was assured at the fi nal colposcopy assessment. The study was suffi ciently powered to address study questions, and participation and drop-out rates seem to have been balanced over the study arms and within acceptable ranges, despite the complex follow-up over more than 3 years. A strong point of TOMBOLA was its integration into the organised screening programmes of England and Scotland, enrolling a relevant population with respect to age, in contrast to the well-known American ASCUS-LSIL Triage Study, which included a rather young population. 5 6 The TOMBOLA Group authors warn against the risk of overdiagnosis and overtreatment by referring all women with minor cytological abnormalities to colposcopy and treating immediately all colposcopically visible lesions by large loop excision of the transformation zone. The authors did not comment on the lower prevalence of CIN3+ in the immediate-colposcopy arm, observed at the fi nal assessment, which could be interpreted as a proxy of lower risk for future cancer. 7 We are looking forward to the study outcomes of TOMBOLA stratifi ed by baseline hrHPV status, which are expected to be published soon. However, we regret the absence of a study arm with management based on HPV status. From the ASCUS-LSIL Triage Study, confi rmed by meta-analyses, it was established that refl ex testing for hrHPV is more effi cient than repeat cytology or immediate-colposcopy referral for triage of ASCUS but not for LSIL, as the large majority of LSIL cases were hrHPV-positive. 5 6 However, at higher age, hrHPV prevalence drops, and HPV-based triage could then become useful, but the defi nition of an age cut-off for LSIL triage remains unclear. 8 We therefore propose new meta-analytical pooling using unpublished data from triage studies, stratifi ed by uniformly defi ned age strata, separated for ASCUS and LSIL, and we hope that the TOMBOLA investigators will contribute to this. Moreover, research is warranted for more specifi c LSIL triage methods for settings where screening will remain cytology based and for triage of HPV-positive women in settings that will switch to screening based on HPV testing.
